10142028Transforming Paediatric Insomnia: A New Sleep Solution for Children to Improve NHS Patient OutcomesActiveCollaborative R&DInnovate UKSleep is a vital component of overall health, yet one-in-three people suffer from insomnia - a condition recognised as a "health epidemic" by the CDC. Over recent years, our understanding of the profound effects that sleep has on both our physical and mental health has grown significantly. A single night of poor sleep can impact a person's mood, alertness and memory. Long-term sleep deprivation can lead to life-threatening conditions such as cardiovascular disease, obesity and depression. Given these factors, the market for effective insomnia treatments is substantial, estimated to be worth $80bn this year. SleepCogni has pioneered a patented Active-Biofeedback therapy, delivered through a unique handheld device. This breakthrough therapy was clinically proven in a randomised-controlled-trial with 80 adults, successfully reducing Clinical Insomnia to Non-Clinical Insomnia in just 7 days and increasing total sleep time by 56 minutes. The aim of this project is develop SleepCogni's paediatric software platform, conduct a clinical trial, real world evidence, of SleepCogni's therapy and platform focusing on SleepCogni's ability to reducing insomnia symptoms among children and adolescents aged between 6 and 16 years.